Azienda Ospedaliero Universitaria di Sassari
Quick facts
Marketed products
- EZE/simvastatin · Cardiovascular
EZE/simvastatin combines ezetimibe (which blocks cholesterol absorption in the intestine) with simvastatin (which inhibits HMG-CoA reductase to reduce cholesterol synthesis) for dual lipid-lowering action.
Phase 3 pipeline
- Ticagrelor orodispersible tablets · Cardiovascular
Ticagrelor is a P2Y12 platelet receptor antagonist that reversibly inhibits ADP-induced platelet aggregation to prevent thrombotic events. - Ticagrelor standard tablets · Cardiovascular
Ticagrelor is a P2Y12 platelet receptor antagonist that reversibly inhibits ADP-induced platelet aggregation to prevent thrombotic events.
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
- Azienda Ospedaliero Universitaria di Sassari portfolio CI brief
- Azienda Ospedaliero Universitaria di Sassari pipeline updates RSS
Frequently asked questions about Azienda Ospedaliero Universitaria di Sassari
What are Azienda Ospedaliero Universitaria di Sassari's marketed drugs?
Top marketed products include EZE/simvastatin.
What is Azienda Ospedaliero Universitaria di Sassari's pipeline?
Azienda Ospedaliero Universitaria di Sassari has 2 drugs in Phase 3, 0 in Phase 2, 0 in Phase 1. Late-stage candidates include Ticagrelor orodispersible tablets, Ticagrelor standard tablets.
Related
- EZE/simvastatin · Cardiovascular
- Sector hub: All tracked pharma companies